Interesting report from Jeffries.
Vistagen Therapeutics
KOL Thinks Novel Anxiety Spray Will Work in Phase III, Has Real-World Use Case
April 18, 2021
Key Takeaway
We spoke to a psychiatrist who thinks VTGN has generated compelling Phase II data for social anxiety, leading him to believe the Phase III studies in 2022 "will be successful." We reiterate our view that the setup at $2/share ($375M cap) looks attractive, as pivotal data starting in Q2:22 could push the stock towards $8/sh ($1.5B+ cap) versus
downside to mostly cash ($100M cap), implying a positive expected value with a 65% PoS assumption. KOL believes existing therapies for social-anxiety disorder (SAD) have serious limitations. He treats over 50+ SAD
patients a month, and his patient breakdown currently includes 60% on SSRIs, 20% benzodiazepines, 10% beta-blockers, and 10%untreated. He affirms: (1) antidepressants..........
Interesting market cap this analyst predicts...
News 
Market Data 
Discover 
